Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

Thomas M. Beck, Paul J. Hesketh, Stefan Madajewicz, Rudolph M. Navari, Kelly Pendergrass, Eric P. Lester, Julie A. Kish, William K. Murphy, John D. Hainsworth, David R. Gandara, Leslie J. Bricker, Alan M. Keller, Joanne Mortimer, Daniel V. Galvin, Karen W. House, Judy C. Bryson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Purpose: This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis. Patients and Methods: This multicenter study was a stratified, randomized, double-blind, and parallel group design. Chemotherapy-naive inpatients were randomized to receive intravenous (IV) ondansetron (Zofran; Glaxo Inc, Research Triangle Park, NC) 0.15 mg/kg times three doses, every 4 hours or a single 8-mg or 32-mg dose followed by two saline doses that began 30 minutes before cisplatin administration. Cisplatin (high-dose ≥ 100 mg/m2 or medium-dose 50 to 70 mg/m2) was given as a single infusion (≤ 3 hours). Patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. Results: A total of 699 patients (359 high-dose, 340 medium-dose) were enrolled. Of these, 618 were assessable for efficacy (15 ineligible, 66 protocol deviations). The 32-mg dose was superior to the 8-mg single dose with regard to total number of emetic episodes (high-dose, P = .015; medium-dose, P < .001), complete response (no emetic episodes: high-dose, 48% v 35%; P = .048; medium-dose, 73% v 50%; P = .001) and failure rate (> 5 emetic episodes, withdrawn or rescued: high-dose, 20% v 34%; P = .018; medium-dose, 9% v 23%; P = .005). The 32-mg single dose was also superior to the 0.15 mg/kg times three dose regimen with regard to total number of emetic episodes (medium-dose, P = .033) and failure rate (high-dose, 20% v 36%; P = .009; medium-dose, 9% v 22%; P = .011). Ondansetron was well tolerated. The most common adverse event was headache. An approximate 10-fold increase in the incidence of clinically significant transaminase elevations was observed in the high-dose versus medium-dose cisplatin strata (asparate aminotransferase [AST], 6.5% v 0.7%; serum alanine aminotransferase [ALT], 5.0% v 0.3%). Conclusion: A 32-mg single dose of ondansetron is more effective than a single 8-mg dose and is at least as effective as the standard regimen of 0.15 mg/kg times three doses in the prevention of cisplatin-induced acute emesis.

Original languageEnglish (US)
Pages (from-to)1969-1975
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number12
StatePublished - 1992

Fingerprint

Ondansetron
Nausea
Cisplatin
Emetics
Vomiting
Transaminases
Safety
Alanine Transaminase
Multicenter Studies
Headache
Inpatients
Drug Therapy
Incidence
Serum
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. / Beck, Thomas M.; Hesketh, Paul J.; Madajewicz, Stefan; Navari, Rudolph M.; Pendergrass, Kelly; Lester, Eric P.; Kish, Julie A.; Murphy, William K.; Hainsworth, John D.; Gandara, David R.; Bricker, Leslie J.; Keller, Alan M.; Mortimer, Joanne; Galvin, Daniel V.; House, Karen W.; Bryson, Judy C.

In: Journal of Clinical Oncology, Vol. 10, No. 12, 1992, p. 1969-1975.

Research output: Contribution to journalArticle

Beck, TM, Hesketh, PJ, Madajewicz, S, Navari, RM, Pendergrass, K, Lester, EP, Kish, JA, Murphy, WK, Hainsworth, JD, Gandara, DR, Bricker, LJ, Keller, AM, Mortimer, J, Galvin, DV, House, KW & Bryson, JC 1992, 'Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting', Journal of Clinical Oncology, vol. 10, no. 12, pp. 1969-1975.
Beck, Thomas M. ; Hesketh, Paul J. ; Madajewicz, Stefan ; Navari, Rudolph M. ; Pendergrass, Kelly ; Lester, Eric P. ; Kish, Julie A. ; Murphy, William K. ; Hainsworth, John D. ; Gandara, David R. ; Bricker, Leslie J. ; Keller, Alan M. ; Mortimer, Joanne ; Galvin, Daniel V. ; House, Karen W. ; Bryson, Judy C. / Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 12. pp. 1969-1975.
@article{7c89a82f8aa9474cbb7458129aff9900,
title = "Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting",
abstract = "Purpose: This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis. Patients and Methods: This multicenter study was a stratified, randomized, double-blind, and parallel group design. Chemotherapy-naive inpatients were randomized to receive intravenous (IV) ondansetron (Zofran; Glaxo Inc, Research Triangle Park, NC) 0.15 mg/kg times three doses, every 4 hours or a single 8-mg or 32-mg dose followed by two saline doses that began 30 minutes before cisplatin administration. Cisplatin (high-dose ≥ 100 mg/m2 or medium-dose 50 to 70 mg/m2) was given as a single infusion (≤ 3 hours). Patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. Results: A total of 699 patients (359 high-dose, 340 medium-dose) were enrolled. Of these, 618 were assessable for efficacy (15 ineligible, 66 protocol deviations). The 32-mg dose was superior to the 8-mg single dose with regard to total number of emetic episodes (high-dose, P = .015; medium-dose, P < .001), complete response (no emetic episodes: high-dose, 48{\%} v 35{\%}; P = .048; medium-dose, 73{\%} v 50{\%}; P = .001) and failure rate (> 5 emetic episodes, withdrawn or rescued: high-dose, 20{\%} v 34{\%}; P = .018; medium-dose, 9{\%} v 23{\%}; P = .005). The 32-mg single dose was also superior to the 0.15 mg/kg times three dose regimen with regard to total number of emetic episodes (medium-dose, P = .033) and failure rate (high-dose, 20{\%} v 36{\%}; P = .009; medium-dose, 9{\%} v 22{\%}; P = .011). Ondansetron was well tolerated. The most common adverse event was headache. An approximate 10-fold increase in the incidence of clinically significant transaminase elevations was observed in the high-dose versus medium-dose cisplatin strata (asparate aminotransferase [AST], 6.5{\%} v 0.7{\%}; serum alanine aminotransferase [ALT], 5.0{\%} v 0.3{\%}). Conclusion: A 32-mg single dose of ondansetron is more effective than a single 8-mg dose and is at least as effective as the standard regimen of 0.15 mg/kg times three doses in the prevention of cisplatin-induced acute emesis.",
author = "Beck, {Thomas M.} and Hesketh, {Paul J.} and Stefan Madajewicz and Navari, {Rudolph M.} and Kelly Pendergrass and Lester, {Eric P.} and Kish, {Julie A.} and Murphy, {William K.} and Hainsworth, {John D.} and Gandara, {David R.} and Bricker, {Leslie J.} and Keller, {Alan M.} and Joanne Mortimer and Galvin, {Daniel V.} and House, {Karen W.} and Bryson, {Judy C.}",
year = "1992",
language = "English (US)",
volume = "10",
pages = "1969--1975",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

AU - Beck, Thomas M.

AU - Hesketh, Paul J.

AU - Madajewicz, Stefan

AU - Navari, Rudolph M.

AU - Pendergrass, Kelly

AU - Lester, Eric P.

AU - Kish, Julie A.

AU - Murphy, William K.

AU - Hainsworth, John D.

AU - Gandara, David R.

AU - Bricker, Leslie J.

AU - Keller, Alan M.

AU - Mortimer, Joanne

AU - Galvin, Daniel V.

AU - House, Karen W.

AU - Bryson, Judy C.

PY - 1992

Y1 - 1992

N2 - Purpose: This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis. Patients and Methods: This multicenter study was a stratified, randomized, double-blind, and parallel group design. Chemotherapy-naive inpatients were randomized to receive intravenous (IV) ondansetron (Zofran; Glaxo Inc, Research Triangle Park, NC) 0.15 mg/kg times three doses, every 4 hours or a single 8-mg or 32-mg dose followed by two saline doses that began 30 minutes before cisplatin administration. Cisplatin (high-dose ≥ 100 mg/m2 or medium-dose 50 to 70 mg/m2) was given as a single infusion (≤ 3 hours). Patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. Results: A total of 699 patients (359 high-dose, 340 medium-dose) were enrolled. Of these, 618 were assessable for efficacy (15 ineligible, 66 protocol deviations). The 32-mg dose was superior to the 8-mg single dose with regard to total number of emetic episodes (high-dose, P = .015; medium-dose, P < .001), complete response (no emetic episodes: high-dose, 48% v 35%; P = .048; medium-dose, 73% v 50%; P = .001) and failure rate (> 5 emetic episodes, withdrawn or rescued: high-dose, 20% v 34%; P = .018; medium-dose, 9% v 23%; P = .005). The 32-mg single dose was also superior to the 0.15 mg/kg times three dose regimen with regard to total number of emetic episodes (medium-dose, P = .033) and failure rate (high-dose, 20% v 36%; P = .009; medium-dose, 9% v 22%; P = .011). Ondansetron was well tolerated. The most common adverse event was headache. An approximate 10-fold increase in the incidence of clinically significant transaminase elevations was observed in the high-dose versus medium-dose cisplatin strata (asparate aminotransferase [AST], 6.5% v 0.7%; serum alanine aminotransferase [ALT], 5.0% v 0.3%). Conclusion: A 32-mg single dose of ondansetron is more effective than a single 8-mg dose and is at least as effective as the standard regimen of 0.15 mg/kg times three doses in the prevention of cisplatin-induced acute emesis.

AB - Purpose: This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis. Patients and Methods: This multicenter study was a stratified, randomized, double-blind, and parallel group design. Chemotherapy-naive inpatients were randomized to receive intravenous (IV) ondansetron (Zofran; Glaxo Inc, Research Triangle Park, NC) 0.15 mg/kg times three doses, every 4 hours or a single 8-mg or 32-mg dose followed by two saline doses that began 30 minutes before cisplatin administration. Cisplatin (high-dose ≥ 100 mg/m2 or medium-dose 50 to 70 mg/m2) was given as a single infusion (≤ 3 hours). Patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. Results: A total of 699 patients (359 high-dose, 340 medium-dose) were enrolled. Of these, 618 were assessable for efficacy (15 ineligible, 66 protocol deviations). The 32-mg dose was superior to the 8-mg single dose with regard to total number of emetic episodes (high-dose, P = .015; medium-dose, P < .001), complete response (no emetic episodes: high-dose, 48% v 35%; P = .048; medium-dose, 73% v 50%; P = .001) and failure rate (> 5 emetic episodes, withdrawn or rescued: high-dose, 20% v 34%; P = .018; medium-dose, 9% v 23%; P = .005). The 32-mg single dose was also superior to the 0.15 mg/kg times three dose regimen with regard to total number of emetic episodes (medium-dose, P = .033) and failure rate (high-dose, 20% v 36%; P = .009; medium-dose, 9% v 22%; P = .011). Ondansetron was well tolerated. The most common adverse event was headache. An approximate 10-fold increase in the incidence of clinically significant transaminase elevations was observed in the high-dose versus medium-dose cisplatin strata (asparate aminotransferase [AST], 6.5% v 0.7%; serum alanine aminotransferase [ALT], 5.0% v 0.3%). Conclusion: A 32-mg single dose of ondansetron is more effective than a single 8-mg dose and is at least as effective as the standard regimen of 0.15 mg/kg times three doses in the prevention of cisplatin-induced acute emesis.

UR - http://www.scopus.com/inward/record.url?scp=0027081530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027081530&partnerID=8YFLogxK

M3 - Article

C2 - 1453211

AN - SCOPUS:0027081530

VL - 10

SP - 1969

EP - 1975

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -